Clinical Trial Update: Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

View source ↗

Summary

A completed special investigation collecting safety and efficacy data for VIZIMPRO (dacomitinib) in EGFR mutation-positive non-small cell lung cancer under Japa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• VIZIMPRO (dacomitinib)

Snippet

Sponsor: Pfizer | Conditions: EGFR Mutation-positive Inoperable or Reccrent NSCLC | Status: COMPLETED